Publication Name	World Journal of Gastroenterology
Manuscript ID	71600
Country	China

Received	2021-09-16 09:57
Peer-Review Started	2021-09-16 09:57
To Make the First Decision
Return for Revision	2021-10-16 01:44
Revised	2021-10-27 10:11
Second Decision	2021-12-07 03:16
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-12-08 05:51
Articles in Press	2021-12-08 05:51
Publication Fee Transferred
Edit the Manuscript by Language Editor	2021-12-02 23:16
Typeset the Manuscript	2021-12-09 03:27
Publish the Manuscript Online	2021-12-17 08:56

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Expert Consensus
Article Title	Chinese experts’ consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma
Manuscript Source	Unsolicited Manuscript
All Author List	Hai-Tao Zhao and Jian-Qiang Cai
ORCID	Author(s) ORCID Number Hai-Tao Zhao http://orcid.org/0000-0002-0727-1108 Jian-Qiang Cai http://orcid.org/0000-0001-6090-7817
Funding Agency and Grant Number
Corresponding Author	Jian-Qiang Cai, MD, Professor, Department of Hepatobiliary Surgery, Cancer Hospital Chinese Academy of Medical Sciences, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. caijianqiang2021@163.com
Key Words	Consensus; Hepatocellular carcinoma; Neoadjuvant therapy; Conversion therapy
Core Tip	Recent studies showed that neoadjuvant therapy for resectable hepatocellular carcinoma (HCC) and conversion therapy for unresectable HCC are safe, feasible, and effective. It was necessary to conduct a widely accepted consensus among the experts in China who have extensive expertise and experience in treating HCC using neoadjuvant and conversion therapies.
Publish Date	2021-12-17 08:56
Citation	Zhao HT, Cai JQ. Chinese experts’ consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma. World J Gastroenterol 2021; 27(47): 8069-8080
URL	https://www.wjgnet.com/1007-9327/full/v27/i47/8069.htm
DOI	https://dx.doi.org/10.3748/wjg.v27.i47.8069

Full Article (PDF)	WJG-27-8069.pdf
Full Article (Word)	WJG-27-8069.docx
Manuscript File	71600_Auto_Edited-JRF-Filipodia Needs CC.docx
Answering Reviewers	71600-Answering reviewers.pdf
Audio Core Tip	71600-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	71600-Conflict-of-interest statement.pdf
Copyright License Agreement	71600-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	71600-Language certificate.pdf
Supplementary Material	71600-Supplementary material.pdf
Peer-review Report	71600-Peer-review(s).pdf
Scientific Misconduct Check	71600-Bing-Fan JR-2.png
Scientific Editor Work List	71600-Scientific editor work list.pdf